| Ausstehende Aktien | 10,146,516 shares |
| Insider-Aktien | 9.134.131 shares |
| Insider-Besitz | 90,02 % |
| Insider gesamt | 32 |
Insider-Stimmungswert
Der Insider-Stimmungswert ermittelt die Unternehmen, die von Unternehmensinsidern gekauft werden.
Es ist das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Insiderakkumulation identifiziert. Das Scoring-Modell verwendet eine Kombination aus der Nettozahl der Insiderkäufe der letzten 90 Tage, der Gesamtzahl der gekauften Aktien als Prozentsatz des Streubesitzes und der Gesamtzahl der von Insidern gehaltenen Aktien. Die Zahl reicht von 0 bis 100, wobei höhere Zahlen ein höheres Maß an Insiderkäufen anzeigen als bei anderen Unternehmen und 50 den Durchschnitt darstellt.
Aktualisierungshäufigkeit: Täglich
Führungskräfte-Stimmungswert
Der Führungskräfte-Stimmungswert findet Unternehmen, die von Führungskräften des Unternehmens gekauft werden.
Per Definition sind Führungskräfte des Unternehmens Insider, aber im Gegensatz zu anderen Insidern (10%ige Aktionäre und Vorstandsmitglieder) arbeiten Führungskräfte täglich für das Unternehmen und verwenden beim Handel ihr eigenes Geld. (10%ige Aktionäre und Vorstandsmitglieder sind oft Fondsmanager, die das Geld anderer Leute verwalten.) Daher sind Insider-Geschäfte, die von Führungskräften getätigt werden, viel bedeutender und sollten entsprechend behandelt werden.
Wie der Insider-Stimmungswert ist auch der Führungskräfte-Stimmungswert das Ergebnis eines ausgeklügelten quantitativen Multifaktormodells, das die Unternehmen mit der höchsten Führungskräftekonzentration identifiziert.
Aktualisierungshäufigkeit: Täglich
Wichtige Insider-Kennzahlen
Diese Karte zeigt, wie das Unternehmen bei verschiedenen Insider-Kennzahlen abschneidet. Der Perzentil-Rang zeigt, wie dieses Unternehmen im Vergleich zu anderen Unternehmen auf den US-Märkten abschneidet. Höhere Ränge deuten auf eine bessere Situation hin.
Es ist beispielsweise allgemein anerkannt, dass Insiderkäufe ein positiver Indikator sind, so dass Unternehmen mit mehr Insiderkäufen besser abschneiden würden als Unternehmen mit weniger Insiderkäufen (oder sogar Insiderverkäufen).
Prozent des Streubesitzes von Insidern gekauft (Rang)
10775 out of 10791
Prozent des von Insidern gekauften Streubesitzes ist die Gesamtzahl der von Insidern gekauften Aktien abzüglich der Gesamtzahl der von Insidern in den letzten 90 Tagen verkauften Aktien, geteilt durch den gesamten Streubesitz und multipliziert mit 100.
Diagramm zum Insiderhandel
BiomX Inc. Insider-Trades sind in der folgenden Grafik dargestellt. Insider sind leitende Angestellte, Direktoren oder bedeutende Investoren in einem Unternehmen. Im Allgemeinen ist es für Insider illegal, auf der Grundlage von wesentlichen, nicht-öffentlichen Informationen mit Aktien ihrer Unternehmen zu handeln. Das bedeutet nicht, dass es für sie illegal ist, irgendwelche Geschäfte in ihren eigenen Unternehmen zu tätigen. Sie müssen jedoch alle Geschäfte der SEC über ein Formular 4 melden.
Kennzahlen zu Insiderlisten und Rentabilität
Diese Tabelle zeigt die Liste der bekannten Insider und wird automatisch aus den bei der SEC eingereichten Unterlagen erstellt. Zusätzlich zu den Namen, dem letzten Titel und der Bezeichnung als Direktor, leitender Angestellter oder 10%-iger Anteilseigner geben wir die zuletzt veröffentlichten Bestände an. Zusätzlich stellen wir, wenn möglich, die historische Handelsperformance für den Insider zur Verfügung. Die historische Handelsperformance ist ein gewichteter Durchschnitt der Performance tatsächlicher offener Kauftransaktionen, die von dem Insider getätigt wurden. Weitere Informationen zur Berechnung dieses Wertes finden Sie in diesem YouTube-Webinar.
See our leaderboard of most profitable insider traders.
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Gbolahan Amusa Director - [D] | 262.871 | 18.129 | |
| Merav Bassan Chief Development Officer - [O] | 79.597 | 4.189 | |
| Uri Ben-Or | 0 | ||
| Yaron Breski | 16.000 | ||
|
Chardan Investments, LLC
10% Owner -
|
3.940.000 | 3.940.000 | |
|
Erez Chimovits
10% Owner -
|
2.313.489 | 949.907 | |
|
Fibrosis Foundation Cystic
10% Owner -
|
1.787.758 | 94.093 | |
| James E Flynn Director - [D] | 1.247.054 | 65.634 | |
| Jonas Grossman Director - [D] | 372.717 | 25.705 | |
| Richard Giroux Director - [D] | 15.000 | 15.000 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Elliot Gnedy Director - [D] | 15.000 | 15.000 | |
| Russell Greig Director - [D] | 3.750 | 259 | |
| George Kaufman | 0 | ||
| Eric Kusseluk Director - [D] | 15.000 | 15.000 | |
|
MMCAP International Inc. SPC
10% Owner -
|
3.400.000 | 3.400.000 | |
| Alan Charles Moses Director - [D] | 5.000 | 345 | |
|
OrbiMed Israel BioFund GP Limited Partnership
10% Owner -
|
13.773.653 | 949.907 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
2.813.489 | 949.907 | |
| Assaf Oron Chief Business Officer - [O] | 25.804 | 1.358 | |
|
Kerry Propper
10% Owner -
|
0 | 0 | |
| Sailaja Puttagunta | 67.500 |
| Insider | Durchschnittlicher Gewinn (%) | Aktien in Besitz |
Split Angepasst |
|---|---|---|---|
| Yehuda Michael Rice Director - [D] | 15.000 | 15.000 | |
| Matthew Rossen Director - [D] | 15.000 | 15.000 | |
| Paul J Sekhri Director - [D] | 12.500 | 862 | |
| Jonathan Eitan Solomon Chief Executive Officer, Director - [D] [O] | 126.748 | 6.671 | |
| Lynne Marie Sullivan Director - [D] | 12.500 | 862 | |
|
Pharmaceutical Co Ltd Takeda
10% Owner -
|
4.941.870 | 340.819 | |
| Chidozie Ugwumba - | 2.997.025 | 206.691 | |
|
Thomas Layton Walton
10% Owner -
|
0 | 0 | |
| Marina Wolfson Chief Financial Officer - [O] | 68.545 | 3.608 | |
| Robbie Woodman | 0 | ||
|
Reuven Yeganeh
Director, 10% Owner -
[D]
|
0 | 0 |
Report errors via our new Insider Auditing Tool
Erfolgsbilanz der Insiderkäufe - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in PHGE / BiomX Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Erfolgsbilanz von Insiderverkäufen - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in PHGE / BiomX Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch .
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Bereinigter Preis ist der splitbereinigte Preis. Bereinigte Aktien sind die um den Split bereinigten Aktien.
Transaktionshistorie
Klicken Sie auf das Link-Symbol, um den vollständigen Transaktionsverlauf anzuzeigen. Transaktionen, die im Rahmen eines automatischen Handelsplans 10b5-1 gemeldet werden, sind in der Spalte 10b-5 mit einem X gekennzeichnet.
| Datei Datum |
Handel Datum |
Form | Insider | Ticker | Wertpapier-Titel | Code | Direkt | Ausführung Preis |
Einheit Preis |
Eimheiten Verändert |
Wert Geändert (1K) |
Verbleibende Optionen |
Verbleibende Aktien |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-17 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 5,0000 | -530.000 | -2.650 | 0 | ||||
| 2026-03-18 | 2026-03-17 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 2,0000 | 530.000 | 1.060 | 530.000 | ||||
| 2026-03-18 | 2026-03-16 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 5,0000 | -450.000 | -2.250 | 0 | ||||
| 2026-03-18 | 2026-03-16 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 2,0000 | 450.000 | 900 | 450.000 | ||||
| 2026-03-13 | 2026-03-13 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 5,0000 | -370.000 | -1.850 | 0 | ||||
| 2026-03-13 | 2026-03-13 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 2,0000 | 370.000 | 740 | 370.000 | ||||
| 2026-03-13 | 2026-03-12 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 5,0000 | -300.000 | -1.500 | 0 | ||||
| 2026-03-13 | 2026-03-11 | 4 | Yeganeh Reuven Pyu Pyu Capital LLC | PHGE | Common Stock, $0.0001 par value per share | I | 2,0000 | 300.000 | 600 | 30.000 | ||||
| 2025-04-21 | 2025-04-14 | 4/A | Bassan Merav | PHGE | Common Stock | D | 79.597 | 79.597 | ||||||
| 2025-04-21 | 2025-04-14 | 4/A | Solomon Jonathan Eitan | PHGE | Common Stock | D | 126.748 | 126.748 | ||||||
| 2025-04-21 | 2025-04-14 | 4/A | Wolfson Marina | PHGE | Common Stock | D | 68.545 | 68.545 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 126.748 | 126.748 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Bassan Merav | PHGE | Common Stock | D | 79.597 | 79.597 | ||||||
| 2025-04-18 | 2025-04-14 | 4 | Wolfson Marina | PHGE | Common Stock | D | 68.545 | 68.545 | ||||||
| 2025-03-04 | 2024-07-15 | 5 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 854.700 | 1.787.758 | ||||||
| 2025-03-03 | 2025-02-27 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 0,9306 | 353.249 | 329 | 1.247.054 | ||||
| 2025-03-03 | 2025-02-27 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 0,9306 | 353.249 | 329 | 1.247.054 | ||||
| 2024-09-18 | 2024-09-16 | 4 | Bassan Merav | PHGE | Common Stock | D | 31.749 | 31.749 | ||||||
| 2024-09-18 | 2024-09-16 | 4 | Oron Assaf | PHGE | Common Stock | D | 25.804 | 25.804 | ||||||
| 2024-09-18 | 2024-09-16 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 50.556 | 53.056 | ||||||
| 2024-07-17 | 2024-07-15 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 5.883.000 | 8.938.049 | ||||||
| 2024-07-17 | 2024-07-15 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 5.883.000 | 8.938.049 | ||||||
| 2024-05-20 | 2024-05-15 | 4 | OrbiMed Israel BioFund GP Limited Partnership See footnotes | PHGE | Common Stock | I | 0,3812 | -24.344 | -9 | 13.773.653 | ||||
| 2024-05-20 | 2024-05-15 | 4 | OrbiMed Israel BioFund GP Limited Partnership See footnotes | PHGE | Common Stock | I | 0,2440 | 9.280.408 | 2.264 | 13.797.997 | ||||
| 2024-05-17 | 2024-05-15 | 4 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 0,0010 | 4.778.265 | 5 | 9.330.580 | ||||
| 2024-03-26 | 3 | Cystic Fibrosis Foundation | PHGE | Common Stock, par value $0.0001 per share | D | 4.552.315 | ||||||||
| 2024-03-19 | 2024-03-15 | 4 | Flynn James E Through Deerfield Healthcare Innovations Fund II, L.P. | PHGE | Common Stock | I | 3.055.049 | 3.055.049 | ||||||
| 2024-03-19 | 2024-03-15 | 4 | Flynn James E Through Deerfield Private Design Fund V, L.P. | PHGE | Common Stock | I | 3.055.049 | 3.055.049 | ||||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,3400 | -2.056 | -1 | 0 | ||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,3500 | -3.414 | -1 | 2.056 | ||||
| 2023-12-01 | 2023-11-29 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,4000 | -5.444 | -2 | 5.470 | ||||
| 2023-05-24 | 2023-05-22 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2731 | 3.192 | 1 | 10.914 | ||||
| 2023-05-22 | 2023-05-19 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2809 | 6.521 | 2 | 7.722 | ||||
| 2023-05-22 | 2023-05-18 | 4 | Oron Assaf | PHGE | Common Stock | D | 0,2727 | 1.201 | 0 | 1.201 | ||||
| 2023-03-17 | 2023-02-27 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock | I | 0,2450 | 348.000 | 85 | 3.161.489 | ||||
| 2022-11-14 | 2022-11-04 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3780 | -1.501 | -1 | 2.997.025 | ||||
| 2022-11-14 | 2022-11-03 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3660 | -2.000 | -1 | 2.998.526 | ||||
| 2022-11-14 | 2022-11-02 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3590 | -2.416 | -1 | 3.000.526 | ||||
| 2022-11-14 | 2022-11-01 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3640 | -1.300 | -0 | 3.002.942 | ||||
| 2022-11-14 | 2022-10-31 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3710 | -3.300 | -1 | 3.004.242 | ||||
| 2022-11-14 | 2022-10-28 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3560 | -1.526 | -1 | 3.007.542 | ||||
| 2022-11-14 | 2022-10-27 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3640 | -1.505 | -1 | 3.009.068 | ||||
| 2022-11-14 | 2022-10-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3460 | -12.500 | -4 | 3.010.573 | ||||
| 2022-11-14 | 2022-10-25 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3650 | -3.072 | -1 | 3.023.073 | ||||
| 2022-11-14 | 2022-10-24 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3490 | -5.900 | -2 | 3.026.145 | ||||
| 2022-11-14 | 2022-10-21 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3700 | -5.400 | -2 | 3.032.045 | ||||
| 2022-11-14 | 2022-10-20 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3740 | -6.636 | -2 | 3.037.445 | ||||
| 2022-11-14 | 2022-10-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3670 | -4.501 | -2 | 3.044.081 | ||||
| 2022-11-14 | 2022-10-18 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3460 | -15.300 | -5 | 3.048.582 | ||||
| 2022-11-14 | 2022-10-17 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3350 | -8.098 | -3 | 3.063.882 | ||||
| 2022-11-14 | 2022-10-14 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3310 | -3.420 | -1 | 3.071.980 | ||||
| 2022-11-14 | 2022-10-13 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3300 | -11.314 | -4 | 3.075.400 | ||||
| 2022-11-14 | 2022-10-12 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3330 | -9.700 | -3 | 3.086.714 | ||||
| 2022-11-14 | 2022-10-11 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3320 | -5.988 | -2 | 3.096.414 | ||||
| 2022-11-14 | 2022-10-10 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3260 | -10.043 | -3 | 3.102.402 | ||||
| 2022-11-14 | 2022-10-07 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3580 | -24.708 | -9 | 3.112.445 | ||||
| 2022-11-14 | 2022-10-06 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4440 | -25.098 | -11 | 3.137.153 | ||||
| 2022-11-14 | 2022-10-05 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4350 | -46.785 | -20 | 3.162.251 | ||||
| 2022-11-14 | 2022-10-04 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3440 | -19.200 | -7 | 3.209.036 | ||||
| 2022-11-14 | 2022-10-03 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3300 | -15.022 | -5 | 3.228.236 | ||||
| 2022-11-14 | 2022-09-30 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3560 | -8.662 | -3 | 3.243.258 | ||||
| 2022-11-14 | 2022-09-29 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3490 | -3.300 | -1 | 3.251.920 | ||||
| 2022-11-14 | 2022-09-28 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3330 | -15.649 | -5 | 3.255.220 | ||||
| 2022-11-14 | 2022-09-27 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3310 | -4.866 | -2 | 3.270.869 | ||||
| 2022-11-14 | 2022-09-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3550 | -17.528 | -6 | 3.275.735 | ||||
| 2022-11-14 | 2022-09-23 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,3740 | -5.306 | -2 | 3.293.263 | ||||
| 2022-11-14 | 2022-09-22 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4130 | -17.388 | -7 | 3.298.569 | ||||
| 2022-11-14 | 2022-09-21 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4270 | -5.574 | -2 | 3.315.957 | ||||
| 2022-11-14 | 2022-09-20 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4510 | -10.626 | -5 | 3.321.531 | ||||
| 2022-11-14 | 2022-09-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,4850 | -13.870 | -7 | 3.332.157 | ||||
| 2022-11-14 | 2022-09-16 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5130 | -3.200 | -2 | 3.346.027 | ||||
| 2022-11-14 | 2022-09-15 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5310 | -3.900 | -2 | 3.349.227 | ||||
| 2022-11-14 | 2022-09-14 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5230 | -2.301 | -1 | 3.353.127 | ||||
| 2022-11-14 | 2022-09-13 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5250 | -2.201 | -1 | 3.335.428 | ||||
| 2022-11-14 | 2022-09-12 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5410 | -1.700 | -1 | 3.357.629 | ||||
| 2022-11-14 | 2022-09-09 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5180 | -13.219 | -7 | 3.359.329 | ||||
| 2022-11-14 | 2022-09-08 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5220 | -4.592 | -2 | 3.372.548 | ||||
| 2022-11-14 | 2022-09-07 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5280 | -8.846 | -5 | 3.377.140 | ||||
| 2022-11-14 | 2022-09-06 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5450 | -6.403 | -3 | 3.385.986 | ||||
| 2022-11-14 | 2022-09-02 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5460 | -2.001 | -1 | 3.392.389 | ||||
| 2022-11-14 | 2022-09-01 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5460 | -8.297 | -5 | 3.394.390 | ||||
| 2022-11-14 | 2022-08-31 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5490 | -4.540 | -2 | 3.402.687 | ||||
| 2022-11-14 | 2022-08-30 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5660 | -13.487 | -8 | 3.407.227 | ||||
| 2022-11-14 | 2022-08-29 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,5710 | -11.533 | -7 | 3.420.714 | ||||
| 2022-11-14 | 2022-08-26 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6160 | -60.628 | -37 | 3.432.247 | ||||
| 2022-11-14 | 2022-08-25 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7180 | -26.945 | -19 | 3.492.875 | ||||
| 2022-11-14 | 2022-08-24 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6520 | -8.665 | -6 | 3.519.820 | ||||
| 2022-11-14 | 2022-08-23 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6380 | -5.900 | -4 | 3.528.485 | ||||
| 2022-11-14 | 2022-08-22 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6570 | -5.000 | -3 | 3.534.385 | ||||
| 2022-11-14 | 2022-08-19 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6390 | -14.600 | -9 | 3.539.385 | ||||
| 2022-11-14 | 2022-08-18 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6830 | -7.764 | -5 | 3.553.985 | ||||
| 2022-11-14 | 2022-08-17 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,6880 | -21.335 | -15 | 3.561.749 | ||||
| 2022-11-14 | 2022-08-16 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7290 | -8.563 | -6 | 3.583.084 | ||||
| 2022-11-14 | 2022-08-15 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7470 | -7.200 | -5 | 3.591.647 | ||||
| 2022-11-14 | 2022-08-12 | 4 | Ugwumba Chidozie By Symbiosis, LLC | PHGE | Common Stock | I | 0,7340 | -11.406 | -8 | 3.598.847 | ||||
| 2022-11-14 | 2022-08-11 | 4 | Ugwumba Chidozie By Symbiosis, LLC | PHGE | Common Stock | I | 0,7440 | -9.824 | -7 | 3.610.253 | ||||
| 2022-11-14 | 2022-08-10 | 4 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 0,7400 | -17.769 | -13 | 3.620.077 | ||||
| 2022-03-31 | 2022-03-29 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20.500 | 20.500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20.500 | 20.500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20.500 | 20.500 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 41.000 | 41.000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 50.000 | 50.000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 205.000 | 205.000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Bassan Merav | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 100.000 | 100.000 | |||||
| 2022-03-31 | 2022-03-29 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 1,41 | 20.500 | 20.500 | |||||
| 2022-02-14 | 2021-12-31 | 4 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Warrants to purchase Common Stock | I | 5,00 | -1.875.000 | 0 | |||||
| 2022-02-14 | 2021-12-31 | 4 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Common Stock, $0.0001 par value | I | -3.637.846 | 0 | ||||||
| 2022-02-14 | 3 | Ugwumba Chidozie By SymBiosis, LLC | PHGE | Common Stock | I | 3.637.846 | ||||||||
| 2021-08-17 | 2021-07-26 | 4/A | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 37.500 | 372.717 | ||||||
| 2021-08-17 | 2020-07-26 | 4/A | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 5,00 | 28.125 | 28.125 | |||||
| 2021-08-09 | 3 | Walton Thomas Layton By SymBiosis, LLC | PHGE | Common Stock, $0.0001 par value | I | 3.637.846 | ||||||||
| 2021-07-30 | 2021-07-28 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Warrants (Right to Buy) | I | 5,00 | 375.000 | 375.000 | |||||
| 2021-07-30 | 2021-07-28 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.0001 par value | I | 500.000 | 2.813.489 | ||||||
| 2021-07-30 | 2021-07-28 | 4 | Wolfson Marina | PHGE | Common Stock Warrant | D | 5,00 | 2.813 | 2.813 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Wolfson Marina | PHGE | Common Stock | D | 4,0000 | 3.750 | 15 | 3.750 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Warrant | D | 5,00 | 9.375 | 9.375 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Sullivan Lynne Marie | PHGE | Common Stock | D | 4,0000 | 12.500 | 50 | 12.500 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Warrant | D | 5,00 | 18.750 | 18.750 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock | D | 4,0000 | 25.000 | 100 | 25.000 | ||||
| 2021-07-30 | 2021-07-28 | 4 | SEKHRI PAUL J | PHGE | Common Stock Warrant | D | 5,00 | 9.375 | 9.375 | |||||
| 2021-07-30 | 2021-07-28 | 4 | SEKHRI PAUL J | PHGE | Common Stock | D | 4,0000 | 12.500 | 50 | 12.500 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Greig Russell | PHGE | Common Stock Warrant | I | 5,00 | 2.813 | 2.813 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Greig Russell | PHGE | Common Stock | I | 4,0000 | 3.750 | 15 | 3.750 | ||||
| 2021-07-30 | 2021-07-28 | 4 | Moses Alan Charles | PHGE | Common Stock Warrant | D | 5,00 | 3.750 | 3.750 | |||||
| 2021-07-30 | 2021-07-28 | 4 | Moses Alan Charles | PHGE | Common Stock | D | 4,0000 | 5.000 | 20 | 5.000 | ||||
| 2021-07-28 | 2021-07-26 | 4 | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 5,00 | 28.125 | 28.125 | |||||
| 2021-07-28 | 2021-07-26 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 37.500 | 372.217 | ||||||
| 2021-07-28 | 2021-07-26 | 4 | Amusa Gbolahan | PHGE | Warrants to purchase Common Stock | D | 5,00 | 18.750 | 18.750 | |||||
| 2021-07-28 | 2021-07-26 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 25.000 | 262.871 | ||||||
| 2021-04-01 | 2021-03-30 | 4 | Puttagunta Sailaja | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 71.250 | 71.250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 30.400 | 30.400 | |||||
| 2021-04-01 | 2021-03-30 | 4 | SEKHRI PAUL J | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15.200 | 15.200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Oron Assaf | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 33.250 | 33.250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15.200 | 15.200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Bassan Merav | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 47.500 | 47.500 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 33.250 | 33.250 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15.200 | 15.200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 152.000 | 152.000 | |||||
| 2021-04-01 | 2021-03-30 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15.200 | 15.200 | |||||
| 2021-04-01 | 2021-03-30 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 7,02 | 15.200 | 15.200 | |||||
| 2020-10-05 | 2020-10-02 | 4 | SEKHRI PAUL J | PHGE | Common Stock Options - Right to Buy | D | 6,44 | 16.000 | 16.000 | |||||
| 2020-10-05 | 2020-10-02 | 4 | Moses Alan Charles | PHGE | Common Stock Options - Right to Buy | D | 6,44 | 16.000 | 16.000 | |||||
| 2020-07-27 | 2020-07-13 | 4 | Amusa Gbolahan | PHGE | Warrants to purchase Common Stock | D | 11,50 | 276.190 | 276.190 | |||||
| 2020-07-27 | 2020-07-13 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 95.148 | 237.871 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Warrants to purchase Common Stock | I | 11,50 | -2.900.000 | 0 | |||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY | PHGE | Warrants to purchase Common Stock | D | 11,50 | 631.786 | 631.786 | |||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Common Stock, par value $0.0001 | I | -999.058 | 0 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | PROPPER KERRY | PHGE | Common Stock, par value $0.0001 | D | 217.652 | 260.771 | ||||||
| 2020-07-22 | 2020-07-13 | 4 | GROSSMAN JONAS | PHGE | Warrants to purchase Common Stock | D | 11,50 | 666.310 | 716.439 | |||||
| 2020-07-22 | 2020-07-13 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 229.545 | 335.217 | ||||||
| 2020-07-22 | 2020-06-18 | 4 | GROSSMAN JONAS By Ravenna LLC | PHGE | Common Stock, par value $0.0001 | I | -45.275 | 0 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | PROPPER KERRY By Mountain Wood, LLC | PHGE | Common Stock, par value $0.0001 | I | 999.058 | 999.058 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | PROPPER KERRY | PHGE | Common Stock, par value $0.0001 | D | 43.119 | 43.119 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | Amusa Gbolahan | PHGE | Common Stock, par value $0.0001 | D | 142.723 | 142.723 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS By Ravenna LLC | PHGE | Common Stock, par value $0.0001 | I | 42.275 | 45.275 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS By Chardan Investments, LLC | PHGE | Common Stock, par value $0.0001 | I | -1.707.500 | 0 | ||||||
| 2020-06-12 | 2020-06-10 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 99.172 | 105.672 | ||||||
| 2020-03-27 | 2020-03-25 | 4 | Solomon Jonathan Eitan | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 144.000 | 144.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | GROSSMAN JONAS | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16.000 | 16.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Chimovits Erez | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16.000 | 16.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Amusa Gbolahan | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16.000 | 16.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Oron Assaf | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 31.500 | 31.500 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Sullivan Lynne Marie | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16.000 | 16.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Breski Yaron | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 16.000 | 16.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Wolfson Marina | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 36.000 | 36.000 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Puttagunta Sailaja | PHGE | Common Stock Options - Right to Buy | I | 6,21 | 67.500 | 67.500 | |||||
| 2020-03-27 | 2020-03-25 | 4 | Greig Russell | PHGE | Common Stock Options - Right to Buy | D | 6,21 | 32.000 | 32.000 | |||||
| 2019-12-30 | 2019-12-20 | 4 | GROSSMAN JONAS | PHGE | Warrants | I | 11,50 | -2.900.000 | 0 | |||||
| 2019-12-20 | 2019-12-19 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9000 | 3.500 | 31 | 2.313.489 | ||||
| 2019-12-20 | 2019-12-18 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9300 | 500 | 4 | 2.309.989 | ||||
| 2019-12-20 | 2019-12-19 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9000 | 3.500 | 31 | 2.313.489 | ||||
| 2019-12-20 | 2019-12-18 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9300 | 500 | 4 | 2.309.989 | ||||
| 2019-12-12 | 2019-12-11 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9200 | 5.400 | 48 | 2.309.489 | ||||
| 2019-12-12 | 2019-12-10 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,7500 | 3.400 | 30 | 2.304.089 | ||||
| 2019-12-12 | 2019-12-11 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,9200 | 5.400 | 48 | 2.309.489 | ||||
| 2019-12-12 | 2019-12-10 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,7500 | 3.400 | 30 | 2.304.089 | ||||
| 2019-12-09 | 2019-12-09 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,6800 | 6.000 | 52 | 2.300.689 | ||||
| 2019-12-09 | 2019-12-06 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,0000 | 800 | 6 | 2.294.689 | ||||
| 2019-12-09 | 2019-12-05 | 4 | OrbiMed Israel BioFund GP Limited Partnership See Footnotes | PHGE | Common Stock, $0.001 par value | I | 7,9900 | 3.400 | 27 | 2.293.889 | ||||
| 2019-12-09 | 2019-12-09 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,6800 | 6.000 | 52 | 2.300.689 | ||||
| 2019-12-09 | 2019-12-06 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 8,0000 | 800 | 6 | 2.294.689 | ||||
| 2019-12-09 | 2019-12-05 | 4 | Chimovits Erez See Footnotes | PHGE | Common Stock, $0.001 par value | I | 7,9900 | 3.400 | 27 | 2.293.889 | ||||
| 2019-11-20 | 2019-11-20 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 8,0040 | 1.400 | 11 | 6.500 | ||||
| 2019-11-20 | 2019-11-19 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 7,5730 | 4.100 | 31 | 5.100 | ||||
| 2019-11-20 | 2019-11-18 | 4 | GROSSMAN JONAS | PHGE | Warrants | D | 11,50 | 0,5990 | 50.129 | 30 | 50.129 | |||
| 2019-11-20 | 2019-11-18 | 4 | GROSSMAN JONAS | PHGE | Common Stock, par value $0.0001 | D | 6,9890 | 1.000 | 7 | 1.000 | ||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | Chimovits Erez See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-07 | 3 | OrbiMed Israel GP Ltd. See Footnotes | PHGE | Common Stock | I | 4.580.980 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4.941.870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4.941.870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4.941.870 | ||||||||
| 2019-11-05 | 3 | Takeda Ventures, Inc. | PHGE | Common Stock | I | 4.941.870 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3.400.000 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3.400.000 | ||||||||
| 2019-09-19 | 3 | MMCAP International Inc. SPC | CHAC | Common Stock | D | 3.400.000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-21 | 3 | Gnedy Elliot | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-19 | 2018-12-18 | 4 | GROSSMAN JONAS | CHAC | Warrants | I | 11,50 | 0,4000 | 2.900.000 | 1.160 | 2.900.000 | |||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Kusseluk Eric | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3.940.000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3.940.000 | ||||||||
| 2018-12-14 | 3 | GROSSMAN JONAS | CHAC | Common Stock, par value $0.0001 | I | 3.940.000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Rossen Matthew | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | RICE YEHUDA MICHAEL | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3.940.000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3.940.000 | ||||||||
| 2018-12-14 | 3 | Chardan Investments, LLC | CHAC | Common Stock, par value $0.0001 | D | 3.940.000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15.000 | ||||||||
| 2018-12-14 | 3 | Giroux Richard | CHAC | Common Stock, par value $0.0001 | D | 15.000 |
P
Offener Markt oder privater Kauf von nicht-derivativen oder derivativen Wertpapieren
S
Freiverkauf oder privater Verkauf von nicht-derivativen oder derivativen Wertpapieren
A
Gewährung, Vergabe oder sonstiger Erwerb von Wertpapieren des Unternehmens (z. B. eine Option)
C
Umwandlung von Derivaten
D
Verkauf oder Rückübertragung von Wertpapieren an das Unternehmen
F
Zahlung des Ausübungspreises oder der Steuerschuld mit einem Teil der vom Unternehmen erhaltenen Wertpapiere
G
Schenkung von Wertpapieren durch oder an den Insider
K
Aktien-Swaps und ähnliche Absicherungstransaktionen
M
Ausübung oder Umwandlung eines vom Unternehmen erhaltenen derivativen Wertpapiers (z. B. einer Option)
V
Eine freiwillig auf Formular 4 gemeldete Transaktion
J
Sonstige (mit einer Fußnote zur Beschreibung der Transaktion)
